Stiefel Laboratories announces restructuring plan

Stiefel Laboratories has announced the execution of a number of organisational changes at the company which aim to aid the integration of its operations into a single company following its acquisition of Connetics last year.

The firm has created a global marketing team, strengthened the function of its global medical affairs division and moved combined its sales and marketing teams in the US.

As part of this restructuring plan, the company has appointed Bill Humphries to the role of chief commercial officer, a newly-created position with responsibility for all commercial aspects of the business worldwide, including sales, marketing, public relations and strategic communications.

Charles Stiefel, chief executive officer and chairman of the company, said: “This is an exciting time for Stiefel Laboratories.

“The products, technology and the expertise of employees in Palo Alto at the former Connetics expand our product portfolio.”

He added that the company’s research and development pipeline has now been augmented with a number of new potential candidate offerings, with the firm’s new organisation facilitating efficiency worldwide and a stronger global brand.

In January 2007, Stiefel Laboratories appointed Richard J MacKay as vice-chairman of its board of directors, with Mr Mackay also continuing in his role as president of Stiefel Canada.